Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP(R), Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ajinomoto
Contact Ajinomoto, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack